Cargando…

Efficacy of c-Met inhibitor for advanced prostate cancer

BACKGROUND: Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuation of androgen receptor (AR) signalling. This suggested that current androgen ab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tu, William H, Zhu, Chunfang, Clark, Curtis, Christensen, James G, Sun, Zijie
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964640/ https://www.ncbi.nlm.nih.gov/pubmed/20946682 http://dx.doi.org/10.1186/1471-2407-10-556

Ejemplares similares

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
por: Wang, Zhenwei, et al.
Publicado: (2021)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
por: Shao, Zhiwei, et al.
Publicado: (2020)

Isothiocyanatostilbenes as novel c-Met inhibitors
por: Gray, Alana L., et al.
Publicado: (2015)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
por: Crosswell, Hal E, et al.
Publicado: (2009)

Conditional Deletion of the Pten Gene in the Mouse Prostate Induces Prostatic Intraepithelial Neoplasms at Early Ages but a Slow Progression to Prostate Tumors
por: Kwak, Mi Kyung, et al.
Publicado: (2013)

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
por: Zhou, Ji, et al.
Publicado: (2023)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy
por: Etnyre, Deven, et al.
Publicado: (2014)

ZMIZ1 Preferably Enhances the Transcriptional Activity of Androgen Receptor with Short Polyglutamine Tract
por: Li, Xiaomeng, et al.
Publicado: (2011)

The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis
por: Ye, Sa, et al.
Publicado: (2016)

Development of antibody-based c-Met inhibitors for targeted cancer therapy
por: Lee, Dongheon, et al.
Publicado: (2015)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

MET expression during prostate cancer progression
por: Verhoef, Esther I., et al.
Publicado: (2016)

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers
por: Fujita, Ryo, et al.
Publicado: (2020)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
por: Yuan, Qingyun, et al.
Publicado: (2021)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
por: Qin, Shukui, et al.
Publicado: (2019)

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
por: van Leenders, Geert J. L. H., et al.
Publicado: (2011)

The tumour suppressor miR-34c targets MET in prostate cancer cells
por: Hagman, Z, et al.
Publicado: (2013)

High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer
por: JACOBSEN, FRANK, et al.
Publicado: (2013)

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization
por: Chu, Gina Chia-Yi, et al.
Publicado: (2014)

Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met
por: Shu, Yan, et al.
Publicado: (2018)

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
por: De Mello, Ramon Andrade, et al.
Publicado: (2020)

Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors
por: Dong, Xiaorong, et al.
Publicado: (2022)

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
por: Kim, Jooseok, et al.
Publicado: (2020)

MET inhibition enhances PARP inhibitor efficacy in castration‐resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways
por: Zhou, Sihai, et al.
Publicado: (2021)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
por: Mohyeldin, Mohamed M., et al.
Publicado: (2016)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model
por: Sun, Yinggang, et al.
Publicado: (2015)

Multiplexed Quantum Dot Labeling of Activated c-Met Signaling in Castration-Resistant Human Prostate Cancer
por: Hu, Peizhen, et al.
Publicado: (2011)

Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
por: Hwang, Sun Tae, et al.
Publicado: (2020)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7sc8rhfeeknld4ha9crli7brgi